Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients

Kidney International, Supplement

Volumn 63, Issue 84, 2003, Pages

  London, Gérard M ^a,b   Marchais, Sylvain J ^a   Guerin, Alain P ^a   Metivier, Fabien ^a   Adda, Hassan ^a   Pannier, Bruno ^a  

^a Hôpital F H Manhès   (France)

^b Hopital FH Manhes   (France)

Author keywords

Arteriosclerosis; Cardiac hypertrophy; Dialysis; Inflammation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; NITRENDIPINE; PERINDOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AORTA DISEASE; AORTA FLOW; ARTERIOSCLEROSIS; BLOOD CHEMISTRY; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODYNAMICS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFECT; HYPERTENSION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; VASCULITIS;

ADULT; ANTIHYPERTENSIVE AGENTS; AORTIC DISEASES; ARTERIOSCLEROSIS; ATENOLOL; BLOOD PRESSURE; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRENDIPINE; REGRESSION ANALYSIS; RENAL DIALYSIS; VASCULITIS;

EID: 0037406350     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s84.25.x     Document Type: Conference Paper

References (33)

1. US RENAL DATA SYSTEM: USRDA 1991 Annual Report. Bethesda, MD, The National Institute of Diabetes and Digestive and Kidney Diseases, 1991.
2. FOLEY RN, PARFREY PS, HARNETT JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1992
3. SILBERBERG J, BARRE PE, PRICHARD SS, SNIDERMAN AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
4. BLACHER J, GUÉRIN AP, PANNIER B, et al: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434-2439, 1999
5. NICHOLS WW, O'ROURKE MF: Vascular impedance, in McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 4th edition, London, Edward Arnold, pp 243-283, 1998
6. GUÉRIN AP, BLACHER J, PANNIER B, et al: Impact of aortic stiffness attenuation on survival of patients in end-stage renal disease. Circulation 103:987-992, 2001
7. LONDON GM, PANNIER B, GUÉRIN AP, et al: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
8. DEVEREUX RB, REICHER N: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 55:613-618, 1977
9. LONDON GM, PANNIER B, GUÉRIN AP, et al: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
10. LONDON GM, MARCHAIS SJ, GUÉRIN AP, et al: Salt and water retention and calcium blockade in uremia. Circulation 82:103-113, 1992
11. LAURENT S, BOUTOUYRIE P, ASMAR R, et al: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertens 37:1236-1241, 2001
12. SHOJI T, EMOTO M, SHINOHARA K, et al: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12:2117-2124, 2001
13. LONDON GM, GUÉRIN AP, MARCHAIS SJ, et al: Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50:600-608, 1996
14. LONDON GM, GUÉRIN AP, MARCHAIS SJ: Pressure-overload cardiomyopathy in end-stage renal disease Cur Opini Nephrol Hypertens 8:179-186, 1999
15. TOZAWA M, ISEKI K, ISEKI C, et al: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002;61:717-726,2001
16. KLASSEN PS, LOWRIE EG, REDDAN DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
17. RIDKER PM, CUSHMAN M, STAMPFER MJ, et al: Plasma concentration of C-Reactive protein and risk of developing peripheral vascular disease. Circulation 97:425-428, 1998
18. HASHIMOTO H, KITAGAWA K, HOUGAKU H, et al: C-Reactive protein is an independent predictor of the rate of increase in early atherosclerosis. Circulation 104:63-67, 2001
19. OWEN WF, LOWRIE EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
20. ZIMMERMANN J, HERRLINGER S, PRUY A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-655, 1999
21. CHUNG MK, MARTIN DO, SPRECHER D, et al: C-reactive protein elevation in patients with atrial arrthythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 98:946-952, 1998
22. TSUTAMOTO T, WADA A, MATSUMOTO T, et al: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Col Cardiol 37:2086-2092, 2001
23. KALRA DK, ZHU X, RAMCHANDANI MK, et al: Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: A potential mechanism for depressed myocardial finction in hibernating myocardium in humans. Circulation 105:1537-1540, 2002
24. WANNER C, METZGER T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 17[Sup 8]:29-32, 2002
25. PHILLIPS MI, KAGIYAMA S: Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3:569-577, 2002
26. BRASIER AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257-1266, 2002
27. WINGLER K, WUNSH S, KREUTZ R, et al: Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 31:1456-1464, 2001
28. WANG HD, JOHNS DG, XU S, COHEN RA: Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. Am J Physiol Heart Circ Physiol 282:H697-702, 2002
29. SCHINDLER R, DINARELLO CA, KOCH KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin-1 by human peripheral blood mononuclear cells. Cytokine 7:526-533, 1995
30. FUKUZAWA M, SATOH J, SAGARA M, et al: Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 36:49-55, 1997
31. STENVINKEL P, ANDERSON P, WANG T, et al: Do ACE-inhibitors suppress tumor necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246:503-507, 1999
32. (2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J Mol Cell Cardiol 27:2295-2302, 1995
33. MACDOUGALL IC, COOPER AC: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17[Sup 11]:39-43, 2002